List of Excipients in Branded Drug MITOXANTRONE

Generic Drugs Containing MITOXANTRONE

Company	Ingredient	NDC	Excipient
Teva Parenteral Medicines Inc	mitoxantrone	0703-4685	ACETIC ACID
Teva Parenteral Medicines Inc	mitoxantrone	0703-4685	SODIUM ACETATE ANHYDROUS
Teva Parenteral Medicines Inc	mitoxantrone	0703-4685	SODIUM CHLORIDE
Teva Parenteral Medicines Inc	mitoxantrone	0703-4685	WATER
Hospira Inc	mitoxantrone	61703-343	ACETIC ACID
Hospira Inc	mitoxantrone	61703-343	SODIUM ACETATE
Hospira Inc	mitoxantrone	61703-343	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in MITOXANTRONE?

# Of NDCs	Excipient
4	ACETIC ACID
2	SODIUM ACETATE
2	SODIUM ACETATE ANHYDROUS
4	SODIUM CHLORIDE
1	SODIUM METABISULFITE
3	WATER

Last updated: August 19, 2026

Mitoxantrone is a mature, generic injectable with limited composition-of-matter or formulation-patent leverage. The strongest commercial opportunities are excipient-enabled improvements in stability, container compatibility, ready-to-use administration, cytotoxic-drug handling, and supply reliability. Price competition limits the value of a conventional “new formulation” unless it reduces pharmacy labor, drug waste, occupational exposure, or administration time.

Mitoxantrone Excipient Strategy and Commercial Opportunities

What is the current mitoxantrone formulation?

Mitoxantrone hydrochloride is an anthracenedione antineoplastic drug supplied as a sterile intravenous concentrate. The reference product, Novantrone, was marketed as a 2 mg/mL solution in single-use vials. Generic products use substantially similar aqueous formulations.

Attribute	Typical mitoxantrone product profile
Active ingredient	Mitoxantrone hydrochloride
Dosage form	Sterile intravenous solution
Strength	Commonly 2 mg/mL
Route	Intravenous infusion
Primary indications	Acute myeloid leukemia, hormone-refractory prostate cancer, multiple sclerosis
Typical formulation pH	Approximately acidic, generally around pH 3 to 4
Core excipients	Sodium chloride, sodium acetate, acetic acid, water for injection
Preservative	Generally preservative-free, single-dose presentation
Administration	Dilution or infusion under institutional cytotoxic-drug procedures
Regulatory status	Generic small-molecule drug; no biosimilar pathway

The formulation relies on an acidic aqueous vehicle and buffering system rather than a complex solubilization platform. Mitoxantrone hydrochloride is sufficiently water-soluble for an injectable concentrate, reducing the need for surfactants, cosolvents, lipid carriers, or cyclodextrins in the conventional product. The U.S. prescribing information identifies sodium chloride, acetic acid, sodium acetate, and water for injection among the inactive ingredients for the reference formulation.[1]

The primary excipient functions are:

1. Maintaining drug solubility in an acidic environment.
2. Controlling pH during storage.
3. Managing osmolality and dilution compatibility.
4. Supporting chemical stability in the vial and infusion container.
5. Limiting precipitation after dilution into common infusion fluids.

What excipients protect mitoxantrone stability?

The most defensible excipient strategy is a low-complexity acidic buffer system based on sodium acetate and acetic acid, with sodium chloride used for tonicity control.

Acidic pH control

Mitoxantrone hydrochloride is formulated under acidic conditions. An acetate buffer can help control pH across the product’s shelf life and reduce the risk of precipitation or degradation caused by pH drift.

A development program should evaluate:

• Mitoxantrone assay and degradation products across pH 2.5 to 5.0.
• Buffer concentration and buffer capacity.
• Drug concentration at the proposed commercial strength.
• Stability after dilution into 0.9% sodium chloride and 5% dextrose.
• Temperature excursions, including refrigerated and room-temperature storage.
• Light exposure, because colored anthracenedione solutions may have photostability and visual-assessment implications.

A narrow pH target is usually preferable to a high-capacity buffer. Excessive buffer concentration can increase osmolality, affect injection tolerability, and complicate dilution behavior.

Tonicity adjustment

Sodium chloride supports an isotonic or near-isotonic product profile. A reformulation should not assume that increasing sodium chloride improves robustness. Higher ionic strength can change drug-excipient interactions, container adsorption, and precipitation behavior after dilution.

The target should be a clinically acceptable osmolality range supported by stability and infusion studies rather than an arbitrary sodium chloride concentration.

Chelation and antioxidant systems

Routine inclusion of EDTA, metabisulfite, ascorbate, or other antioxidants is not justified without evidence of an oxidative degradation pathway. These excipients can create new regulatory and compatibility risks:

• EDTA may affect container systems and analytical methods.
• Sulfites can create hypersensitivity concerns.
• Ascorbate can alter pH and redox conditions.
• Additional excipients increase extractables, leachables, and toxicological documentation.

The preferred first-line approach is oxygen-controlled manufacturing, low-headspace filling, suitable container closure, and light protection rather than an unneeded antioxidant package.

Surfactants and cosolvents

Polysorbates, polyethylene glycol, propylene glycol, ethanol, and cyclodextrins are unlikely to provide a clear benefit for the conventional 2 mg/mL solution. Their inclusion could create risks involving:

• Peroxide-mediated degradation.
• Container closure interaction.
• Infusion tolerability.
• New impurity profiles.
• More complex regulatory justification.

These excipients may become relevant only if a higher-concentration, low-volume, intramuscular, subcutaneous, oral, or long-acting formulation is pursued.

What formulation patents protect mitoxantrone?

The conventional mitoxantrone injectable is unlikely to have meaningful remaining composition-of-matter or basic formulation-patent protection in major markets. Mitoxantrone was discovered and commercialized decades ago, and multiple generic injectable products have entered the market.

IP category	Current commercial significance
Mitoxantrone molecule	Historical patent rights are expired or commercially exhausted in major markets
Conventional aqueous injection	Low apparent exclusivity value; generic competition exists
Acetate-buffered formulation	Limited differentiation unless tied to a specific stability or administration claim
Method-of-use patents	Potentially relevant only for narrow disease, dosing, or treatment-duration claims
Container or device claims	Possible source of differentiated protection
Ready-to-use presentation	Potentially protectable through formulation, packaging, or device claims
Manufacturing process	Potentially valuable as know-how, but difficult to protect broadly
New delivery system	Highest remaining patent opportunity

A new patent position would be more credible for a specific technical improvement than for the known use of acetate, sodium chloride, or water for injection. Potential claim categories include:

• A defined pH and buffer-capacity range.
• Reduced-degradation formulations at higher drug concentration.
• A stable ready-to-use infusion bag.
• A low-sorption or low-leachables container system.
• A closed-system transfer device integrated with the product.
• A formulation that reduces preparation steps or cytotoxic exposure.
• A lyophilized presentation with demonstrated reconstitution and stability.
• A sustained-release or depot system, if clinically viable.

A formulation patent would need to show more than routine optimization. Comparative data should establish unexpected stability, reduced waste, improved administration, lower exposure risk, or a clinically relevant pharmacokinetic benefit.

When does mitoxantrone lose exclusivity?

Mitoxantrone has already lost the principal forms of U.S. regulatory exclusivity associated with a new small-molecule product. The commercial market is generic, and the principal reference product is no longer protected by a meaningful period of market exclusivity.

FDA approval of generic mitoxantrone products under abbreviated new drug applications confirms that a conventional immediate-release injectable can be supported through an ANDA pathway when the product meets quality, bioequivalence, sterility, and labeling requirements.[2]

The key commercial implication is that an excipient change will not automatically create premium pricing. A product must deliver measurable value to hospitals, oncology pharmacies, or distributors.

What is the Orange Book status of mitoxantrone?

Mitoxantrone is an Orange Book-listed small-molecule drug, not a biologic. The Orange Book is relevant to reference-listed-drug status, therapeutic-equivalence evaluations, patents, and regulatory exclusivity. It is not a biosimilar product.

For a current product assessment, the commercially relevant questions are:

• Whether the proposed product references the correct listed drug.
• Whether the dosage form and strength match the reference product.
• Whether the product is therapeutically equivalent.
• Whether any listed patent or exclusivity remains active.
• Whether a Paragraph IV certification is required.

Because the core mitoxantrone injection market is mature, Paragraph IV litigation is unlikely to be the primary barrier for a new conventional generic. A new entrant would face more practical risk from sterile manufacturing capacity, quality-system performance, procurement contracts, and shortages than from an active patent thicket.

Which companies are challenging mitoxantrone exclusivity?

The market is characterized by generic manufacturers rather than active branded-versus-generic patent competition. Generic availability has been reported through manufacturers and distributors such as Hikma, Sagent, Teva, and other approved suppliers, depending on jurisdiction and product presentation.[2,3]

The competitive question is therefore not primarily which company is filing a Paragraph IV challenge. It is which supplier can provide:

• Reliable sterile injectable capacity.
• Consistent raw-material supply.
• Competitive institutional pricing.
• Low reject and recall rates.
• Multiple vial sizes.
• Adequate inventory during oncology-drug shortages.
• Improved pharmacy handling.

Company participation and market availability can change by country and over time. FDA Drugs@FDA, the Orange Book, DailyMed, and current wholesaler listings should control product-specific conclusions.[2-4]

What excipient-based commercial opportunities exist for mitoxantrone?

Ready-to-use infusion products

A ready-to-use mitoxantrone infusion bag could reduce pharmacy compounding steps. The commercial value would depend on demonstrated in-use stability, container compatibility, storage conditions, and hospital workflow savings.

Potential benefits include:

• Lower preparation labor.
• Lower risk of calculation and dilution errors.
• Reduced cytotoxic-drug handling.
• Lower vial overfill and residual waste.
• Faster dose administration.

The main barrier is shelf-life. A ready-to-use product may require a larger container, greater storage volume, and more demanding leachables and stability studies.

Premixed low-volume presentations

A premixed product at a clinically useful dose could occupy a middle position between a vial and a full infusion bag. It may be attractive where hospitals use standardized doses or protocols.

The formulation must address:

• Drug adsorption to bags and tubing.
• Concentration changes during storage.
• Visual inspection of a strongly colored product.
• Compatibility with polyolefin, PVC, multilayer films, and elastomeric components.
• Stability after connection to infusion systems.

Low-sorption and low-leachables packaging

Packaging may produce more defensible value than a new excipient. Candidate systems include:

• Cyclic olefin polymer or cyclic olefin copolymer components.
• Low-sorption multilayer infusion bags.
• Fluoropolymer-lined administration sets.
• Light-protective overwraps.
• Elastomers selected for reduced extractables.

The development program should quantify drug recovery after contact with the full administration pathway, not only the primary vial.

Closed-system transfer compatibility

Mitoxantrone is a cytotoxic drug. A product designed for compatibility with closed-system transfer devices could reduce occupational exposure and simplify pharmacy handling.

Commercial differentiation could come from a validated package comprising:

• A vial and stopper optimized for transfer.
• A proprietary adapter or connector.
• A ready-to-use transfer pathway.
• Reduced surface contamination.
• Compatibility with existing oncology pharmacy systems.

The product would need human-factors, device, extractables, sterility, and container-closure data. Device integration may create a stronger IP position than an excipient-only change.

Lyophilized mitoxantrone

A lyophilized presentation could improve storage flexibility or reduce degradation if liquid stability is limiting. It would also introduce:

• Reconstitution time.
• Cake appearance and residual moisture requirements.
• Reconstitution volume and agitation requirements.
• Additional pharmacy manipulation.
• Potential dosing errors.

Lyophilization is therefore more attractive for markets with liquid stability or cold-chain constraints than for U.S. hospitals already using a stable liquid generic.

Higher-concentration formulation

A higher-concentration product could reduce infusion volume and packaging waste. The development risks include increased precipitation, local tolerability concerns, viscosity, and greater sensitivity to pH and ionic strength.

A higher-concentration product could support patent claims if it delivers unexpected stability or a clinically useful reduction in administration volume. It would not be commercially compelling solely because it contains less water.

How strong is the mitoxantrone patent estate?

The conventional mitoxantrone patent estate is weak from a blocking-rights perspective and moderate from a formulation-development perspective.

Factor	Assessment
Basic molecule	Weak remaining exclusivity position
Conventional injectable	Low blocking strength
Generic regulatory pathway	Established
Excipient innovation	Moderate opportunity if supported by comparative data
Device integration	Stronger potential than routine excipient substitution
Manufacturing know-how	Important operational barrier
Sterile injectable capacity	High practical barrier
Hospital contracting	Significant commercial barrier
Biosimilar exposure	Not applicable

The strongest moat is likely to come from a combined product system rather than from a single excipient. A stable premix, validated container, proprietary transfer device, and supply contract could create practical differentiation even without broad patent exclusivity.

What manufacturing and IP barriers affect mitoxantrone?

Manufacturing risk is more important than basic patent risk.

Sterile manufacturing

Mitoxantrone requires aseptic processing, validated sterilization controls, container-closure integrity, and control of visible and subvisible particles. Sterile injectable failures can cause costly supply interruptions and regulatory action.

Cytotoxic containment

Manufacturing and packaging facilities need controls for worker exposure, cross-contamination, cleaning validation, and waste handling. These requirements increase capital expenditure and reduce the number of qualified facilities.

Primary packaging

The product’s intense color can complicate visual inspection and particulate detection. Container selection must account for sorption, permeability, extractables, leachables, and light exposure.

Supply chain

Mitoxantrone hydrochloride API supply, sterile filling, vial availability, and oncology-distribution contracts can determine market access. A supplier that offers dependable availability may win institutional business despite having no formulation patent.

What FDA regulatory pathway applies to a new mitoxantrone formulation?

A conventional generic injectable generally follows the ANDA pathway if it matches the reference product in active ingredient, dosage form, strength, route, and other relevant attributes. A materially different formulation may require a 505(b)(2) application, particularly when it introduces a new delivery system, new route, materially different excipients, or new clinical-use claims.[5]

Potential regulatory routes include:

Product concept	Likely regulatory issue
Same 2 mg/mL vial with equivalent excipients	ANDA-type generic development
Different buffer or container with same dosage form	ANDA feasibility depends on sameness and labeling
Ready-to-use infusion bag	May require additional stability, compatibility, and CMC justification
Higher-concentration product	May require clinical bridging and safety justification
New route or long-acting system	Likely 505(b)(2) or full development pathway
Device-integrated cytotoxic system	Drug-device combination requirements may apply

The excipient strategy should be selected with the regulatory pathway in mind. A commercially attractive innovation that triggers extensive clinical development may not be viable in a low-priced generic market.

How does mitoxantrone compare with competing oncology injectables?

Mitoxantrone competes with older cytotoxic products on price, availability, protocol familiarity, and pharmacy workload. Its formulation opportunity differs from newer targeted therapies because the active ingredient is inexpensive and the clinical market is mature.

Product type	Main differentiation lever
Conventional mitoxantrone vial	Price and supply reliability
Mitoxantrone premix	Labor reduction and lower preparation risk
Mitoxantrone device system	Occupational-safety and workflow benefits
Liposomal anthracycline	Pharmacokinetic and toxicity profile, but higher development cost
Oral oncology product	Convenience, but different exposure and adherence risks
Biologic oncology product	Biosimilar and interchangeability issues, not applicable to mitoxantrone

A liposomal or long-acting mitoxantrone program would have greater technical and patent potential but would also require substantially more pharmacology, toxicology, clinical, and manufacturing investment.

What generic launch scenarios exist for mitoxantrone?

Conventional low-price generic

This is the lowest-risk pathway. It depends on manufacturing efficiency, reliable API supply, and institutional contracting. Margins are likely to remain limited where multiple suppliers are active.

Premium premix

A premixed infusion or pharmacy-ready presentation could command a premium if it documents labor savings and reduces preparation waste. Hospital adoption would depend on reimbursement, formulary policy, and purchasing contracts.

Cytotoxic handling platform

A product bundled with a transfer adapter or closed-system workflow could support differentiated pricing. The commercial buyer would be the oncology pharmacy or hospital system rather than the individual prescriber.

Shortage-resilience supplier

A manufacturer with redundant sites, larger safety stock, and reliable delivery could obtain value through group purchasing organization contracts. This strategy depends more on operations than on patent protection.

What licensing opportunities exist for mitoxantrone?

The most credible licensing opportunities involve enabling technologies:

• Low-sorption infusion bags.
• Cytotoxic-compatible administration sets.
• Closed-system transfer devices.
• Sterile premix manufacturing.
• Lyophilization platforms.
• Long-term stability and packaging technology.
• Regional sterile-fill capacity.

A license for a routine acetate-buffered formulation would have limited value because the formulation concept is straightforward and generic competition is established. A license becomes more defensible when it combines proprietary packaging, device compatibility, validated stability, and regulatory-ready data.

No major current branded licensing structure is required to commercialize a standard generic mitoxantrone injection. Commercial deals are more likely to involve contract manufacturing, regional distribution, or device integration than rights to the active pharmaceutical ingredient.

What is the revenue exposure for a mitoxantrone formulation program?

Mitoxantrone revenue exposure is concentrated in a relatively small market for an older oncology and neurology injectable. A conventional product should be modeled as a volume-and-supply business rather than a high-margin specialty product.

Revenue drivers include:

• Number of approved suppliers.
• Hospital contract wins.
• Dose frequency in oncology and multiple sclerosis.
• Availability of alternative therapies.
• Drug-shortage conditions.
• Vial size and residual waste.
• Premix adoption.
• Regional reimbursement and procurement systems.

A premium formulation must generate measurable savings in pharmacy labor, waste, safety compliance, or inventory management. Without those benefits, payers and hospitals are likely to treat the product as therapeutically interchangeable with lower-cost generic vials.

Key Takeaways

• Mitoxantrone is a mature generic injectable with limited remaining basic patent leverage.
• The conventional formulation uses an acidic aqueous vehicle with acetate buffering and sodium chloride.
• A routine excipient substitution is unlikely to support durable premium pricing.
• The strongest opportunities involve ready-to-use presentations, low-sorption packaging, cytotoxic-handling systems, and supply reliability.
• A higher-concentration or lyophilized product could create technical differentiation but would carry added regulatory and development risk.
• Paragraph IV litigation and biosimilar competition are not the main commercial risks.
• Sterile manufacturing, cytotoxic containment, packaging compatibility, and hospital contracting are more important barriers.
• A 505(b)(2) strategy may be appropriate for materially novel delivery systems, but the market may not support the required investment without a clear clinical or workflow benefit.

FAQs

Can sodium chloride be replaced in a mitoxantrone injection?

Possibly, but replacement requires evaluation of osmolality, pH, stability, precipitation, infusion compatibility, and regulatory sameness. Sodium chloride is not merely a filler; it contributes to the product’s ionic environment and tonicity.

Is a preservative-containing mitoxantrone multidose vial commercially attractive?

Usually not. Mitoxantrone is a cytotoxic injectable, and a multidose presentation would create additional sterility, preservative-exposure, handling, and contamination concerns. A preservative-free single-dose product is generally more consistent with oncology pharmacy practice.

Could a ready-to-use mitoxantrone bag receive new patent protection?

Yes, if claims cover a specific stable formulation, container system, concentration, storage condition, or integrated transfer system supported by comparative data. A generic premix concept alone would be vulnerable to obviousness and enablement challenges.

Is mitoxantrone suitable for a liposomal formulation?

Technically, a liposomal approach may be feasible, but it would require extensive development to establish loading efficiency, particle-size control, release behavior, stability, pharmacokinetics, and clinical benefit. The opportunity is greater for a differentiated oncology product than for a low-cost generic strategy.

What is the best commercial excipient strategy for a new mitoxantrone entrant?

The most practical strategy is a simple, preservative-free, acetate-buffered aqueous formulation paired with optimized container closure and a pharmacy-ready presentation. The value proposition should focus on stability, low waste, reduced preparation, and cytotoxic-drug handling rather than on excipient novelty alone.

References

1. U.S. Food and Drug Administration. (2012). Novantrone (mitoxantrone hydrochloride) injection prescribing information. FDA.

2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. National Library of Medicine. (n.d.). DailyMed: Mitoxantrone hydrochloride injection. National Library of Medicine.

4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. FDA.

5. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). FDA.